Format

Send to

Choose Destination
Cornea. 2007 Oct;26(9):1035-8.

Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops.

Author information

1
Department of Ophthalmology, Cukurova University, Faculty of Medicine, Adana, Turkey. altanoz@cu.edu.tr

Abstract

PURPOSE:

To evaluate the efficacy of topical cyclosporin A 0.05% in the management of severe allergic conjunctivitis.

METHODS:

Seven patients with severe allergic conjunctivitis who were not responding to topical steroids, antihistamines, and mast cell stabilizers were given topical cyclosporin A 0.05%. All patients had an active disease when they were included in the study. Signs and symptoms were recorded before and after treatment.

RESULTS:

Seven patients, 6 boys and 1 girl, 6-14 years old, 6 with vernal keratoconjunctivitis and 1 with atopic keratoconjunctivitis, were enrolled in the study. Treatment with topical cyclosporin A 0.05% decreased the severity of symptoms and clinical signs significantly after 6 months (P < 0.05, Wilcoxon signed rank test). In addition, the need for steroids was reduced or even stopped. The patients experienced no side effects during the follow-up periods (mean, 14.0 +/- 2.1 months; range, 8-18 months).

CONCLUSIONS:

Topical cyclosporin A is an effective treatment in the management of severe allergic conjunctivitis with a benefit as a steroid-sparing agent.

PMID:
17893529
DOI:
10.1097/ICO.0b013e31812dfab3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center